Members of the epidermal growth factor receptor (EGFR) and c-Src tyrosine kinase families are frequently co-overexpressed in human neoplasias. This co-overexpression suggests that members of the two families may functionally interact to affect tumor formation and/or progression. Results from recent studies in both a model fibroblast system and in human breast cancer cell lines and tumor tissues have indicated that c-Src and EGFR synergistically interact to promote tumor formation. Evidence also supports a functional interaction between c-Src and two other members of the EGFR family, HER2 and HER3. The potentiation of EGFR-mediated tumor formation by c-Src correlates with EGF-induced physical association of the EGFR with c-Src, c-Src-dependent phosphorylation of the receptor at two novel sites (Y845 and Yl101), and increased tyrosine phosphorylation of selected receptor substrates. Substitution of phenylalanine for Y845 ablates EGF- and serum-induced DNA synthesis, suggesting that phosphorylation of Y845 may be a critical regulator of EGF-mediated growth and may represent a novel target to be exploited for tumor therapy. However, whether this site is required for malignant transformation mediated by the EGFR is not known, nor is the mechanism of phospho-Y845 (pY845) action understood. Similarly, the mechanism of the interplay between HER2/3 and c-Src is unknown. To further investigate the dependency of EGF-induced breast cancer cell growth and tumorigenesis on pY845 and the nature of the HER2/3/c-Src interaction, the ability of an inducibly expressed mutant Y845F EGFR or microinjected peptides containing pY845 to inhibit breast cancer cell growth in culture or in nude mice will be directly tested, as will biological synergism between c-Src and EGFR and its dependency on Y845 phosphorylation in a transgenic mouse model. The downstream effectors of phosphorylated Y845 will also be identified from a panel of known EGFR substrates and from differential phage display libraries, using phosphorylated vs. unphosphorylated peptides containing Y845 as probes. Finally the influence of c-Src on HER2/3-promoted cell survival, growth, and migration will be explored in two cell culture/xenograft models that will allow one to investigate the interaction in a normal (not transformed) cell context. The long-term goal of these studies is to understand the biological consequences of c-Src/EGFR family member interactions and the biochemical mechanisms that underlie them, thereby identifying potential new targets for therapeutic intervention of breast and other cancers.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA071449-10
Application #
7033078
Study Section
Metabolic Pathology Study Section (MEP)
Program Officer
Perry, Mary Ellen
Project Start
1997-04-16
Project End
2008-03-31
Budget Start
2006-04-01
Budget End
2008-03-31
Support Year
10
Fiscal Year
2006
Total Cost
$288,254
Indirect Cost
Name
University of Virginia
Department
Microbiology/Immun/Virology
Type
Schools of Medicine
DUNS #
065391526
City
Charlottesville
State
VA
Country
United States
Zip Code
22904
Demory, Michelle L; Boerner, Julie L; Davidson, Robert et al. (2009) Epidermal growth factor receptor translocation to the mitochondria: regulation and effect. J Biol Chem 284:36592-604
Marozkina, Nadzeya V; Stiefel, Steven M; Frierson Jr, Henry F et al. (2008) MMTV-EGF receptor transgene promotes preneoplastic conversion of multiple steroid hormone-responsive tissues. J Cell Biochem 103:2010-8
Ishizawar, R C; Miyake, T; Parsons, S J (2007) c-Src modulates ErbB2 and ErbB3 heterocomplex formation and function. Oncogene 26:3503-10
Amorino, G P; Deeble, P D; Parsons, S J (2007) Neurotensin stimulates mitogenesis of prostate cancer cells through a novel c-Src/Stat5b pathway. Oncogene 26:745-56
Riggins, Rebecca B; Thomas, Keena S; Ta, Huy Q et al. (2006) Physical and functional interactions between Cas and c-Src induce tamoxifen resistance of breast cancer cells through pathways involving epidermal growth factor receptor and signal transducer and activator of transcription 5b. Cancer Res 66:7007-15
Boerner, Julie L; Biscardi, Jacqueline S; Silva, Corinne M et al. (2005) Transactivating agonists of the EGF receptor require Tyr 845 phosphorylation for induction of DNA synthesis. Mol Carcinog 44:262-73
Boerner, Julie L; Gibson, Matthew A; Fox, Emily M et al. (2005) Estrogen negatively regulates epidermal growth factor (EGF)-mediated signal transducer and activator of transcription 5 signaling in human EGF family receptor-overexpressing breast cancer cells. Mol Endocrinol 19:2660-70
Ishizawar, Rumey C; Tice, David A; Karaoli, Themistoclis et al. (2004) The C terminus of c-Src inhibits breast tumor cell growth by a kinase-independent mechanism. J Biol Chem 279:23773-81
Boerner, Julie L; Demory, Michelle L; Silva, Corinne et al. (2004) Phosphorylation of Y845 on the epidermal growth factor receptor mediates binding to the mitochondrial protein cytochrome c oxidase subunit II. Mol Cell Biol 24:7059-71
Kloth, Michael T; Laughlin, Kristen K; Biscardi, Jacqueline S et al. (2003) STAT5b, a Mediator of Synergism between c-Src and the Epidermal Growth Factor Receptor. J Biol Chem 278:1671-9

Showing the most recent 10 out of 18 publications